A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries.


Journal

Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361

Informations de publication

Date de publication:
05 2020
Historique:
received: 08 11 2019
revised: 09 01 2020
accepted: 20 01 2020
pubmed: 8 2 2020
medline: 20 7 2021
entrez: 8 2 2020
Statut: ppublish

Résumé

To evaluate the characteristics, clinical information, and storage instructions contained in package inserts from medical abortion commodities collected in low- and middle-income countries. From November 2017 to February 2018 mifepristone, misoprostol, and combined mifepristone-misoprostol (combipack) products were collected to populate the Medical Abortion Commodities Database. We extracted stated indications for use, storage instructions, and date of last revision from each package insert obtained. For those inserts listing medical abortion as an indication, we also extracted eligibility criteria, recommended regimens, side effects, and contraindications. We identified 41 package inserts from 20 countries; 19 (46%) listed medical abortion as an indication including all 7 combipacks, all 7 mifepristone products, and 5/27 (19%) misoprostol products. Date of last insert revision ranged from 1991 to 2016. Gestational age limits for early medical abortion ranged from 49 days to "first trimester." Three (43%) mifepristone products recommended a 600 mg oral dose and two (29%) recommended regimens with gemeprost. Eighteen (67%) misoprostol and one (14%) combipack inserts recommended protection from moisture. The characteristics, clinical information, and storage instructions in medical abortion product package inserts from a variety of field settings in low- and middle-income countries included inadequate storage instructions and outdated gestational age limits and regimens. There is an urgent need to revisit approved inserts for medical abortion products in low- and middle-income countries to ensure information is accurate and reflects the current evidence base. Simultaneously, providing supplemental instructions targeted at users may fill some gaps. People have a right to accurate information to ensure a safe and effective medical abortion experience.

Identifiants

pubmed: 32032639
pii: S0010-7824(20)30030-5
doi: 10.1016/j.contraception.2020.01.011
pii:
doi:

Substances chimiques

Abortifacient Agents 0
Misoprostol 0E43V0BB57
Mifepristone 320T6RNW1F
gemeprost 45KZB1FOLS
Alprostadil F5TD010360

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

315-320

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Laura J Frye (LJ)

Gynuity Health Projects, 220 East 42nd Street Suite 710, NY, NY 10017, USA. Electronic address: LFrye@gynuity.org.

Catherine Kilfedder (C)

International Planned Parenthood Federation, 4 Newhams Row, London SE1 3UZ, UK.

Jennifer Blum (J)

Gynuity Health Projects, 220 East 42nd Street Suite 710, NY, NY 10017, USA.

Beverly Winikoff (B)

Gynuity Health Projects, 220 East 42nd Street Suite 710, NY, NY 10017, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH